Company attributes
Venture Capital Firm attributes
Other attributes
Excalibur Fund Managers is a London, England based venture capital firm. They are focused solely on science and entrepreneurship in human medicines. Excalibur Fund Managers are investors, practictioners, scientists, adviser, enabler, facilitator and provider of medical and healthcare facilities.
Founded in 1996 by Sir Christopher Evans, Excalibur manages three funds, the Merlin Fund I, the Merlin Biosciences Fund, and MBF III. Across the three funds, they raised and managed a total of €450 million in 34 equity investments.
Excalibur Fund Managers has made investments in Ardana Bioscience, Neurotech, Plethora Solutions, Destination Skin, Cyclacel Pharmaceuticals, Takeda Cambridge, Intercytex Group, Onyvax, Microscience, Piramed, BioVex, Noxxon Pharma and ReNeuron Group.
They have exited their investments in ReNeuron Group, Noxxon Pharma, Cyclacel Pharmaceuticals, BioVex, Vectura, EpiCept Corporation, Arakis Limited, Energist, Plethora Solutions, Piramed and Microscience.
